文献速递肝病

未治疗慢性丁型肝炎患者中HBV RNA与HBcrAg的差异模式

Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta.
PubMed 文献 · J Hepatol · 2024-12-09

在三个欧盟中心连续入组240例未治疗慢性丁型肝炎患者,检测血清HBV RNA和HBcrAg。仅8%患者HBV RNA阳性,77%患者HBcrAg≥3 log10 U/ml,68%呈HBV RNA阴性/HBcrAg阳性分离模式。作者认为需进一步研究揭示其分子机制。

要点

  • 未治疗慢性丁型肝炎患者中仅8%血清HBV RNA阳性,77% HBcrAg≥3 log10 U/ml。
  • 68%患者呈HBV RNA阴性/HBcrAg阳性分离模式,9%双阳性,23%双阴性。
  • HBV RNA与男性及可检测HBV DNA正相关,HBcrAg阳性与更高HBsAg水平相关。

核心结论

  • 未治疗慢性丁型肝炎患者多数HBV RNA检测不到但HBcrAg可定量,呈分离模式,且多数HBeAg阴性。
  • 作者认为需要进一步研究以揭示这些发现背后的分子机制。

研究设计与样本

  • 横断面研究,连续入组三个欧盟中心的未治疗慢性丁型肝炎患者,共240例。
  • 收集临床和病毒学特征,用Cobas® 6800实时研究性检测定量血清HBV RNA,用LUMIPULSE® G HBcrAg检测定量HBcrAg。
  • 18例有肝活检的患者进行了肝内分析。

主要发现

  • 240例患者中位年龄46岁,62%男性,53%肝硬化,57%接受核苷(酸)类似物治疗,中位ALT 70 U/L,中位HBsAg 3.8 log10 IU/ml,88% HBeAg阴性,中位HDV RNA 4.9 log10 IU/ml。
  • HBV RNA阳性(>10 copies/ml)仅占8%(中位40 [13-82,000] copies/ml),HBcrAg≥3 log10 U/ml占77%(中位4.2 [3.0-8.0] log10 U/ml)。
  • 23%双阴性(HBV RNA/HBcrAg),9%双阳性,68% HBV RNA阴性/HBcrAg阳性。
  • HBV RNA水平与男性及可检测HBV DNA正相关,HBcrAg阳性与更高HBsAg水平相关。
  • 双阳性患者更年轻、非欧洲裔,ALT和HDV RNA水平升高,并可检测到HBV DNA;肝内HDV RNA和HBV RNA在多数样本中阳性,肝内共价闭合环状DNA水平低。

局限性

  • 作者在结论中提出需要进一步研究以揭示这些发现背后的分子机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Serum HBV RNA and hepatitis B core-related antigen (HBcrAg) levels have been proposed as useful biomarkers in the management of patients with HBV; however, their role in chronic hepatitis delta (CHD) is currently unknown. METHODS: Consecutive untreated patients with CHD were enrolled in a cross-sectional study in three EU centers. Clinical and virological characteristics were collected. Serum HBV RNA and HBcrAg levels were quantified by an automated real-time investigational assay (Cobas® 6800, Roche Diagnostics, Pleasanton, Ca, USA) and by LUMIPULSE® G HBcrAg assay (Fujirebio Europe), respectively. In 18 patients with available liver biopsies, intrahepatic analyses were performed. RESULTS: Overall, 240 patients with HDV were enrolled: median age 46 years, 62% male, 53% with cirrhosis, 57% nucleos(t)ide analogue treated, median ALT 70 U/L, median HBsAg 3.8 log10 IU/ml, 88% HBeAg negative, and median HDV RNA 4.9 log10 IU/ml. HBV RNA was positive (>10 copies/ml) in only 8% of patients (median 40 [13-82,000] copies/ml), whereas HBcrAg was ≥3 log10 U/ml in 77% (median 4.2 [3.0-8.0] log10 U/ml). By combining these biomarkers, three categories were identified: 23% double negative (HBV RNA/HBcrAg), 9% double positive (HBV RNA/HBcrAg) and 68% HBV RNA negative/HBcrAg positive. HBV RNA levels positively correlated with male sex and detectable HBV DNA, while positive HBcrAg correlated with higher HBsAg levels. Double-positive patients were younger, non-European, with elevated ALT and HDV RNA levels and detectable HBV DNA. Intrahepatic HDV RNA and HBV RNA were positive in most samples, while intrahepatic levels of covalently closed circular DNA were low. CONCLUSIONS: In untreated CHD, most patients had undetectable HBV RNA but quantifiable HBcrAg ("divergent pattern") in the absence of HBeAg. Additional studies aiming to unravel the molecular mechanisms underlying these findings are warranted. IMPACT AND IMPLICATIONS: Serum HBV RNA and HBcrAg (hepatitis B core-related antigen) are promising biomarkers of the transcriptional activity of covalently closed circular DNA in chronic HBV infection; however, their role in patients with HBV-HDV coinfection is unknown. At variance with what is commonly observed in HBV-monoinfected patients, HBV RNA was undetectable and HBcrAg detectable in the serum of most patients with HDV ("divergent pattern"). The understanding of the viral interplay between HBV and HDV is crucial to dissect the pathogenic mechanisms associated with the distinct phenotypes of patients with HDV.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Degasperi E, Scholtes C, Testoni B, et al. Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta. J Hepatol. 2024. PMID: 39662705. doi:10.1016/j.jhep.2024.11.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。